April 21, 2021 - CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces lipid nanoparticle formulation and development for mRNA vaccine delivery services to research communities, aiming to help researchers solve challenges they might have, for example, traditional vaccine might induce major immunogenicity issues in human body, and regular mRNA vaccine shows compromising ability in administration, trafficking, and delivery in clinical trials.
mRNA vaccines recently have received widespread attention due to their ability to tackle various unmet therapeutical issues that cannot be solved by traditional vaccine technology. For example, live attenuated vaccines sometimes exhibit safety hazards and may induce pathogenic diseases. Lipid nanoparticles (LNPs) stand as the most frequently used non-viral vector that can efficiently bind and condense RNA, protect against degradation in the extracellular space and localize the payload at the membrane of the desired target cell, followed by cellular uptake and endosomal escape into the cytosol.
To address the scientific research need of LNPs mRNA vaccines, various services now are offered by CD Bioparticles to help scientists design and screen the suitable cationic liposomal cargos for mRNA vaccine encapsulation and delivery, and optimize the liposomal cargos for R&D purposes, including for imaging and tracking purpose and for active targeting purpose; and CD Bioparticles can also offer services in lipid library development for mRNA vaccine development, and function and performance analysis and evaluation.
CD Bioparticles specializes in a range of formulation and drug delivery technologies, and this lipid nanoparticle formulation and development service have many benefits, such as being highly stable as the LNP shield protects mRNA from degrading, large payloads and low risks compared to other administration pathways/vectors, and being easy for future modification to enhance the delivery efficiency.
"Our services have many features, for example, LNP encapsulated mRNA vaccine can be delivered to the cytosol efficiently. Particle size is the key parameter that determines the LNP accumulation in DCs, at CD Bioparticles, LNP can be designed to target the DCs via chemical modification or ligand conjugation, and adjuvants can be incorporated in LNPs to assist in immune activation." said Prof. Jeffrey A. Depaul, M.D., the chief scientific officer of R&D department of CD Bioparticles.
"At CD Bioparticles, we work closely with our customers and collaborators to find the best suitable drug delivery solutions to meet their needs. We now offer services to support lipid library development for drug delivery, and also offer a large number of pre-formed liposome, biopolymer & synthetic polymer reagents to our clients for research use." said Dr. Robin J. Watts, the product portfolio manager of CD Bioparticles.
For more detailed information on services of lipid nanoparticle formulation and development for mRNA vaccine delivery, please visit CD Bioparticles at https://www.cd-bioparticles.net/.
About CD Bioparticles
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. It specializes in a range of formulation and drug delivery technologies, from conventional liposomes, PEGylated liposomes for drug delivery to polymer microspheres and nanoparticles for enhanced drug delivery. It provides contract services of drug delivery formulation developments for basic research, formulation feasibility studies, process development and scale-up, formulation characterization, analytical and nonclinical services.
Contact Information
Richard J. Gray
Cd Bioparticles
11967
